New obesity discovery rewrites decades of fat metabolism science
November 24, 2025 / Obesity research / fat metabolism / HSL protein / lipodystrophy insights / metabolic disease
New research reveals HSL protein’s nuclear role in fat cells, linking its absence to lipodystrophy. This breakthrough reshapes understanding of fat metabolism and highlights shared risks between obesity and fat-loss disorders, advancing metabolic disease insights.
Distinct metabolic associations of subcutaneous and visceral adipocyte morphology in women with or without obesity
November 21, 2025 / visceral fat / insulin resistance / adipocyte morphology / adiponectin leptin ratio / obesity biomarkers
This study found that enlarged visceral adipocytes are more strongly linked to metabolic dysfunction in women without obesity, highlighting the adiponectin/leptin ratio as a key biomarker for adipocyte health and insulin resistance across different body compositions.
Microprotein plays vital role in fat accumulation
November 24, 2025 / adipogenin microprotein / fat cell storage / lipid metabolism / metabolic disease therapy / seipin complex
Researchers identified adipogenin as a key microprotein that stabilizes seipin, enabling healthy fat storage in adipocytes. This discovery offers a potential therapeutic target for metabolic conditions like obesity, diabetes, lipodystrophy, and fatty liver disease.
Pharmacists Lead the Shift Toward Comprehensive, Evidence-Based Obesity Care
November 24, 2025 / pharmacist obesity care / GLP-1 therapy / chronic disease management / cardiometabolic health / obesity treatment access
Dr. Diana Isaacs emphasizes the evolving role of pharmacists in treating obesity as a chronic disease, highlighting their impact on medication management, patient counseling, and overcoming barriers to care, especially in the use of GLP-1 and dual incretin therapies.
Aged blood vessel cells play key role in the development of metabolic disorders
November 20, 2025 / senescent cells / metabolic disorders / fisetin therapy / vascular aging / diabetes inflammation
Cedars-Sinai researchers found that senescent blood vessel cells drive metabolic dysfunction in obesity and diabetes. Removing these cells or treating with the senolytic compound fisetin reduced inflammation, improved glucose control, and offers promise for age-related disease therapies.
New Research Reveals That This Popular Spice Has Powerful Anti-Obesity Effects
November 20, 2025 / black cumin benefits / anti-obesity spice / cholesterol reduction / fat cell inhibition / metabolic health
Black cumin (Nigella sativa) demonstrated anti-obesity and lipid-lowering effects in a human trial, improving cholesterol profiles and reducing fat cell formation. Its bioactive compounds, including thymoquinone, may offer therapeutic potential for metabolic and cardiovascular health.
Nonlinear association of serum copper-zinc ratio with overweight/obesity in children and adolescents
November 24, 2025 / copper zinc ratio / childhood obesity / metabolic risk marker / oxidative stress imbalance / obesity prevention tool
A large NHANES study found a nonlinear, positive association between serum copper-zinc ratio and overweight/obesity in children and adolescents. This biomarker may serve as a valuable tool for early metabolic risk assessment and targeted obesity prevention strategies.
Genetic factors behind impulsive choices tied to metabolic and mental health
November 24, 2025 / delay discounting genetics / impulsive behavior health / metabolic mental link / obesity risk genes / psychiatric trait markers
UC San Diego researchers identified 11 genetic regions linked to impulsive decision-making (delay discounting), revealing shared pathways with metabolic and mental health conditions like obesity, diabetes, and mood disorders. This trait may serve as a predictive marker for broad health risks.
Midlife Weight Loss May Trigger Unexpected Brain Inflammation
November 21, 2025 / midlife weight loss / brain inflammation risk / hypothalamic changes / obesity neurohealth link / cognitive decline obesity
A study from Ben-Gurion University found that midlife weight loss, while improving metabolic markers, may trigger temporary hypothalamic inflammation. This neuroinflammatory response raises concerns about potential cognitive risks and underscores the need for age-specific weight loss strategies.
Study links obesity severity to escalating cardiometabolic and renal disease burden
November 18, 2024 / obesity severity risk / cardiometabolic disease burden / renal disease obesity / BMI disease correlation / targeted obesity treatment
A large U.S. study links increasing obesity severity with a stepwise rise in cardiometabolic and renal disease risk. Individuals with Class IV obesity face dramatically higher odds, underscoring the urgent need for early, targeted intervention across all obesity classes.
Weight loss to treat midlife obesity: Protecting the aging brain may be key
November 18, 2025 / midlife weight loss / brain inflammation obesity / hypothalamic response aging / metabolic brain link / age-specific obesity care
BGU researchers found that while midlife weight loss improves metabolic health, it may trigger temporary hypothalamic inflammation. These findings highlight the need for age-specific obesity interventions that protect brain health while managing metabolic risk.
GLP-1s May Improve Colon Cancer Outcomes
November 19, 2025 / GLP-1 colon cancer / obesity cancer outcomes / GLP-1 survival benefit / metabolic cancer therapy / colon cancer obesity
GLP-1 receptor agonists significantly reduced 5-year mortality in patients with colon cancer and severe obesity. This real-world study suggests GLP-1s may offer protective effects beyond glucose control, including anti-inflammatory and anti-tumor benefits in high-risk populations.
Chemerin receptor structures disclose new mechanism of lipid metabolism
November 21, 2025 / chemerin lipid metabolism / GPCR arrestin signaling / obesity inflammation therapy / GPR1 receptor structure / metabolic disease targets
Researchers revealed the molecular structure of GPR1 and its interaction with β-arrestins, uncovering a new mechanism by which chemerin regulates lipid metabolism. These findings offer novel therapeutic targets for obesity and metabolic inflammation via arrestin-biased GPCR signaling.
Ilant Health Enhances Comprehensive Cardiometabolic Care with Direct Contracting for Obesity Management Medicine for Employers
November 21, 2025 / obesity medication access / employer health benefits / cardiometabolic care model / transparent drug pricing / holistic obesity management
Ilant Health is partnering with Eli Lilly to offer direct contracting and transparent pricing for obesity medications, enabling employers to expand access, reduce cost variability, and deliver evidence-based, holistic cardiometabolic care through a predictive, whole-person care model.
Scientists observe metabolic activity of individual lipid droplets in real time
November 19, 2025 / lipid droplet metabolism / real-time cell imaging / metabolic disease research / ATGL enzyme activity / liver cancer lipid
Researchers developed a fluorescent probe, LipiPB Red, to visualize real-time lipid droplet metabolism in living cells. This reveals droplet-specific activity and heterogeneity, especially in liver cancer cells, offering new insights into lipid metabolism and potential metabolic disease therapies.
Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease
November 24, 2025 / MASLD progression map / liver fibrosis signaling / lipid-associated macrophages / spatial liver metabolomics / MASH therapeutic targets
A spatial multi-omics study of MASLD identified MITF-regulated macrophages as key lipid regulators and revealed fibrotic crosstalk and phospholipid accumulation in MASH. These findings offer new mechanistic insights and therapeutic targets for progressive liver disease.
Differences between therapeutic mechanisms of resmetirom and semaglutide against MASH in western diet-fed MC4R-knockout mice
November 20, 2025 / resmetirom semaglutide comparison / MASH treatment mechanisms / liver fibrosis reduction / muscle mass loss / MC4R knockout model
In a MASH mouse model, resmetirom and semaglutide both improved liver outcomes but via distinct mechanisms. Resmetirom enhanced energy expenditure, while semaglutide reduced fibrosis and lean mass, suggesting differing therapeutic effects with potential clinical implications for muscle preservation.
Research trial reveals new way to treat patients with major cause of liver disease
November 20, 2025 / semaglutide MASH treatment / fatty liver drug / weight-independent liver benefit / chronic liver disease / ESSENCE trial findings
A secondary analysis of the ESSENCE trial shows semaglutide significantly improves MASH outcomes, even in patients without major weight loss, suggesting liver benefits may occur through weight-independent mechanisms—marking a major advance in chronic liver disease treatment.
This fatty liver disease diagnosis reminded me heroes are human
November 24, 2025 / Dan Marino MASH / fatty liver awareness / metabolic liver disease / athlete health conditions / MASH public figures
Dan Marino’s recent MASH diagnosis underscores that metabolic liver disease can affect anyone, including elite athletes. This personal narrative highlights the universality of MASH and the importance of recognizing it early—regardless of past health or fame.